Sir -The prognosis of patients with high-grade malignant Thirteen such studies were found, and in 10 of these, the chemotherapy was a single agent nitrosourea. Six of these 10 studies reported survival times, two relapse-free intervals and two, both. We decided to use survival rates as our measure (1985) 40Gy/5 weeks/10 fractions 220mgm -. In each1 case, th1e cycle length1 was 6-w wee (s or 50Gy/5 weeks/20 fractions (Table I ). The radiotherapy regimes employed in the various Walker et al. (1980) 60Gy/6-7 weeks/20-35 fractions studies did not differ greatly, being generally between 5,000 Brisman et al. (1976) 3OGy/3 weeks to brain and 6,000cGy (Table II) . +30Gy/3 weeks to tumour
We looked at survival rates at 6, 12, 18 and 24 months in Walker et al. (1978) 5OGy/5-6 weeks/25-30 fractions each treatment group, and calculated an overall difference Chang et al. (1983) 60 Gy/7 weeks/35 fractions weighted in a manner which takes into account the size of EORTC (1978) 55-60Gy each trial. The results at 12 and 24 months are summarised Garret et at. (1978) 45Gy/4 weeks in Table III . The overall differences at 12 and 24 months were statistically significant -approximately 9% better survival in the nitrosourea patients at 12 months (P=0.002) and carrying the most weight in the overview -were and 3.5% at 24 months (P=0.046). organised by the BTSG (2 studies, (Walker et al., 1978 ; There are some important limitations to these data -1980), the Scandinavian Glioblastoma Study Group (SGSG, firstly, the problem of publication bias -positive results are 1985), and one jointly by the RTOG and the ECOG (Chang more likely to be published than negative results -and we et al., 1983), and we have some reason to believe that these have used only published studies. However, the 4 largest -large cooperative groups publish their results regardless of outcome. Secondly, incomplete data meant we had to omit some trials, while several of those used gave survival information in graphical form, from which we had to read the survival rates. An assumption we had to make in calculating standard errors was that all patients had complete follow-up, which was inlikely to be uniformly true. Finally, we have no measure of the quality of life of these patients. We would conclude that there is evidence, admittedly limited, that a course of nitrosourea only, given adjuvant to radiotherapy, does increase survival of high-grade glioma patients by a small amount. The challenge is to find a chemotherapy combination which will enhance this apparent improvement.
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